Neoplasms, Pulmonary
10
1
2
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
30.0%
3 terminated out of 10 trials
62.5%
-24.0% vs benchmark
10%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Precision Lung Cancer Survivorship Care Intervention
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
A Phase I Study of iPS Cell Generation From Patients With COPD
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy